Year: 2020

Baudax Bio Reports Third Quarter 2020 Financial Results

Written by Customer Service on November 9, 2020. Posted in Public Companies.

ANJESO®Launch Underway; Over 50 Institutions have Added ANJESO to Their Formularies with Users Giving Highly Positive Feedback and Average Monthly Orders Increasing over 125% Since LaunchSecured and Implemented Permanent J-Code for ANJESO from CMS October 1, Along with Two Major Group Purchasing Agreements with Vizient and PremierManagement to Host Investor Conference Call and Webcast Today at 9:00 a.m. ETMALVERN, Pa., Nov. 09, 2020 (GLOBE NEWSWIRE) — Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today reported financial results for the three and nine months ended September 30, 2020.“The third quarter of 2020 was marked by several important achievements, including continued progress with the commercial launch of ANJESO, the securing of group purchasing agreements with two...

Sol-Gel to Present at Upcoming Healthcare Investor Conferences in November 2020

Written by Customer Service on November 9, 2020. Posted in Public Companies.

NESS ZIONA, Israel, Nov. 09, 2020 (GLOBE NEWSWIRE) — Sol-Gel Technologies (NASDAQ: SLGL), (“Sol-Gel”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that the company will present at the following upcoming virtual investor conferences.H.C. Wainwright 6th Annual Israel ConferenceJefferies Virtual London Healthcare ConferenceA live webcast of the presentations will be available under the “Events and Presentations” in the investors section of the Company’s website at www.sol-gel.com.About Sol-Gel TechnologiesSol-Gel is a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Sol-Gel leverages...

Great Elm Capital Corp. Announces Third Quarter 2020 Financial Results Highlighted by Net Investment Income of $0.18 per Share

Written by Customer Service on November 9, 2020. Posted in Public Companies.

WALTHAM, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) — Great Elm Capital Corp. (“we,” “us,” “our,” “GECC,” or “Great Elm BDC”), (NASDAQ: GECC), a business development company (BDC), today announced its financial results for the third quarter ended September 30, 2020.Financial HighlightsNet investment income (“NII”) for the quarter increased quarter-over-quarter to $1.9 million, as compared to NII of $0.9 million for the quarter ended June 30, 2020, as the Company reported a full period of NII following the strategic repositioning of its portfolio in the prior quarterNII per share increased to $0.18, as compared to NII per share of $0.09 for the quarter ended June 30, 2020As of September 30, 2020, Great Elm BDC’s asset coverage ratio was approximately 150.9%, up from 144.5% as of June 30, 2020 and up from 141.1% as of March 31, 2020, compared...

Reata Pharmaceuticals, Inc. Announces Third Quarter 2020 Financial Results and Provides an Update on Business Operations and Clinical Development Programs

Written by Customer Service on November 9, 2020. Posted in Earnings Releases And Operating Results.

REPORTED POSITIVE YEAR 2 DATA FROM THE PIVOTAL CARDINAL STUDY OF BARDOXOLONE METHYL IN PATIENTS WITH CHRONIC KIDNEY DISEASE CAUSED BY ALPORT SYNDROMEREPORTED LONG TERM EFFICACY DATA FROM EAGLE (OPEN-LABEL EXTENSION) STUDY REPORTED POSITIVE BASELINE-CONTROLLED STUDY DATA FROM THE MOXIE EXTENSION STUDY PROVIDED TO FDAENROLLMENT CONTINUES IN FALCON STUDY OF BARDOXOLONE METHYL IN AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASEBARCONA STUDY ENROLLMENT ONGOINGPLANO, Texas, Nov. 09, 2020 (GLOBE NEWSWIRE) — Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced financial results for the quarter ended September 30, 2020, and provided an update on the Company’s business operations and clinical development programs.Clinical and Regulatory UpdateBardoxolone...

Zynerba Pharmaceuticals Reports Third Quarter 2020 Financial Results and Operational Highlights

Written by Customer Service on November 9, 2020. Posted in Earnings Releases And Operating Results.

DEVON, Pa., Nov. 09, 2020 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today reported financial results for the third quarter ended September 30, 2020, and provided an overview of recent operational highlights.“We made good clinical, operational and regulatory progress during the third quarter of 2020 including presenting new data from the pivotal CONNECT-FX and Phase 2 BRIGHT trials, and completing our discussions with the FDA to clarify our clinical path forward to late stage clinical trials in patients with certain developmental and epileptic encephalopathies,” said Armando Anido, Chairman and Chief Executive Officer of Zynerba. “The fourth quarter of this year is another important...

Bonanza Creek Announces Transformative Agreement to Acquire Restructured HighPoint Resources

Written by Customer Service on November 9, 2020. Posted in Mergers And Acquisitions.

Creates a company of scale in the rural DJ Basin with production of 50,000 Boe/d and a consolidated, contiguous leasehold position of approximately 206,000 net acresAccretive on all key financial metrics with a transformative impact on sustainable free cash flow generationDENVER, Nov. 09, 2020 (GLOBE NEWSWIRE) — Bonanza Creek Energy, Inc. (“Bonanza Creek” or the “Company”) (NYSE: BCEI) and HighPoint Resources Corporation (“HighPoint”) (NYSE: HPR) today announced that they have entered into a definitive merger agreement to combine Bonanza Creek and HighPoint in a transaction valued at approximately $3761 million as of November 6, 2020. The transaction value is based on the equity to be issued to HighPoint equity holders, the equity and debt to be issued to HighPoint debt holders in connection with the Exchange Offer (as defined below)...

Brown & Brown, Inc. Announces the Asset Acquisition of CoverHound and CyberPolicy

Written by Customer Service on November 9, 2020. Posted in Mergers And Acquisitions.

DAYTONA BEACH, Fla., Nov. 09, 2020 (GLOBE NEWSWIRE) — J. Scott Penny, Chief Acquisitions Officer of Brown & Brown, Inc. (NYSE:BRO), and Keith Moore, the CEO of CoverHound and its wholly owned subsidiary CyberPolicy (collectively, “CoverHound”), today announced that a subsidiary of Brown & Brown, Inc. has acquired substantially all of the assets of CoverHound.CoverHound is a leading digital insurance marketplace for individuals and small businesses. As one of the original InsurTechs that have emerged and scaled over the past decade, CoverHound has remained true to its vision, focusing on being a trusted advisor for curated choice and meeting the complex demands of today’s modern customer, all while simplifying the insurance comparison and purchasing process. Following the transaction, CoverHound will continue to operate...

Form 8.3 – Urban&Civic Plc

Written by Customer Service on November 9, 2020. Posted in Mergers And Acquisitions.

FORM 8.3PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BYA PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”)1. KEY INFORMATION2. POSITIONS OF THE PERSON MAKING THE DISCLOSUREIf there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)All interests and all short positions should be disclosed.Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should...

Visteon to Present at Baird Global Industrial Conference on Nov. 12

Written by Customer Service on November 9, 2020. Posted in Public Companies.

VAN BUREN TOWNSHIP, Mich., Nov. 09, 2020 (GLOBE NEWSWIRE) — Visteon Corporation (Nasdaq: VC), a leading global supplier of vehicle cockpit electronics, will present at the Baird 2020 Global Industrial Conference on Thursday, Nov. 12. Sachin Lawande, president and CEO, and Jerome Rouquet, senior vice president and chief financial officer, will begin their presentation at 8:30 a.m. ET and then participate in a question-and-answer session. The presentation and Q&A session are expected to last approximately 30 minutes.A live audio webcast of the discussion, together with any related materials, will be accessible through Visteon’s website at https://investors.visteon.com/events-presentations. A replay will be available following the event.About VisteonVisteon is a global technology company that designs, engineers and manufactures...

Silvercorp Files Preliminary Base Shelf Prospectus

Written by Customer Service on November 9, 2020. Posted in Public Companies.

VANCOUVER, British Columbia, Nov. 09, 2020 (GLOBE NEWSWIRE) — Silvercorp Metals Inc. (“Silvercorp” or the “Company”) (TSX/NYSE American: SVM) announced today it has filed a preliminary short form base shelf prospectus with the securities regulators in each province of Canada, except for the Province of Quebec, and a corresponding shelf registration statement on Form F-10 with the U.S. Securities and Exchange Commission (the “SEC”). When made final or effective, the prospectus and registration statement will allow the Company to offer up to US$200 million of common shares, preferred shares, debt securities, warrants, subscription receipts or any combination thereof (“Securities”) during the 25 month period that the shelf prospectus is effective. The specific terms of any offering of Securities, including the use of proceeds...

Year: 2020

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals